SIOX
NASDAQSio Gene Therapies Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Latest news
25 items- PRSio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per SharePARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the Secretary of State of the State of Delaware, as contemplated by the Plan of Complete Liquidation and Dissolution (the "Plan") previously approved by Sio's Board of Directors and stockholders, on February 7, 2024. The Certificate of Dissolution, which is expected to become effective at 4:00 p.m. Eastern Time on February 7, 2024 (the "Effective Time"), provides for the dissolution of Sio under the General Corporation Law of the State of Delaware (the "DGCL"). In connection with the filing of th
- SECSEC Form 15-12G filed by Sio Gene Therapies Inc.15-12G - Sio Gene Therapies Inc. (0001636050) (Filer)
- SECSEC Form EFFECT filed by Sio Gene Therapies Inc.EFFECT - Sio Gene Therapies Inc. (0001636050) (Filer)
- SECSEC Form POS AM filed by Sio Gene Therapies Inc.POS AM - Sio Gene Therapies Inc. (0001636050) (Filer)
- SECSEC Form S-8 POS filed by Sio Gene Therapies Inc.S-8 POS - Sio Gene Therapies Inc. (0001636050) (Filer)
- SECSEC Form 25-NSE filed by Sio Gene Therapies Inc.25-NSE - Sio Gene Therapies Inc. (0001636050) (Subject)
- SECSEC Form 25 filed by Sio Gene Therapies Inc.25 - Sio Gene Therapies Inc. (0001636050) (Filer)
- SECSio Gene Therapies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Sio Gene Therapies Inc. (0001636050) (Filer)
- SECSEC Form DEFA14A filed by Sio Gene Therapies Inc.DEFA14A - Sio Gene Therapies Inc. (0001636050) (Filer)
- SECSio Gene Therapies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Sio Gene Therapies Inc. (0001636050) (Filer)
- SECSEC Form DEFM14A filed by Sio Gene Therapies Inc.DEFM14A - Sio Gene Therapies Inc. (0001636050) (Filer)
- SECSEC Form DEFA14A filed by Sio Gene Therapies Inc.DEFA14A - Sio Gene Therapies Inc. (0001636050) (Filer)
- SECSio Gene Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sio Gene Therapies Inc. (0001636050) (Filer)
- PRSio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results– Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively – Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period – $46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022. "Our financial results continue to show the beneficial effects on operating expenses and cash burn resulting from the termination
- SECSEC Form 10-Q filed by Sio Gene Therapies Inc.10-Q - Sio Gene Therapies Inc. (0001636050) (Filer)
- 13D/GSEC Form SC 13G/A filed by Sio Gene Therapies Inc. (Amendment)SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)
- 13D/GSEC Form SC 13G filed by Sio Gene Therapies Inc.SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)
- NEWS12 Health Care Stocks Moving In Thursday's Pre-Market SessionGainers Cardiovascular Systems (NASDAQ:CSII) shares moved upwards by 48.4% to $19.75 during Thursday's pre-market session. The market value of their outstanding shares is at $827.1 million. The company's, Q2 earnings came out yesterday. AnPac Bio-Medical Science (NASDAQ:ANPC) stock rose 25.93% to $11.8. The company's market cap stands at $24.0 million. Genetic Technologies (NASDAQ:GENE) shares rose 22.6% to $1.79. The company's market cap stands at $27.5 million. Ontrak (NASDAQ:OTRKP) stock increased by 14.28% to $1.92. Organovo Holdings (NASDAQ:ONVO) stock rose 12.37% to $2.18. The market value of their outstanding shares is at $18.9 million. Addex Therapeutics (NASDAQ:ADXN) shares in
- NEWSWhy Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day SessionGainers Crown ElectroKinetics Corp. (NASDAQ:CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Core Scientific, Inc. (NASDAQ:CORZ) rose 65% to $0.4125. B. Riley Financial issued an open letter to Core Scientific shareholders and lenders. Scopus BioPharma Inc. (NASDAQ:SCPS) shares jumped 58.1% to $0.3711 after declining 4% on Wednesday. Icosavax, Inc. (NASDAQ:ICVX) shares climbed 42.9% to $12.75. Icosavax shares jumped 112% on Wednesday after the company provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against respiratory syncytial virus IMV Inc. (NASDAQ:IMV) surged 34.4%
- NEWSWhy Planet Labs Shares Are Trading Higher; Here Are 28 Stocks Moving PremarketGainers Scopus BioPharma Inc. (NASDAQ:SCPS) shares rose 74.7% to $0.4104 in pre-market trading after declining 4% on Wednesday. Surrozen, Inc. (NASDAQ:SRZN) shares rose 67.3% to $0.7291 in pre-market trading. The company, last month, posted a narrower Q3 loss. Crown ElectroKinetics Corp. (NASDAQ:CRKN) rose 54.1% to $0.2366 in pre-market trading after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Core Scientific, Inc. (NASDAQ:CORZ) rose 53% to $0.3826 in pre-market trading after B. Riley Financial issued an open letter to Core Scientific shareholders and lenders. Jounce Therapeutics, Inc. (NASDAQ:JNCE) shares rose 23.4% to $0.8499 in
- PRSio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and DissolutionNEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets, including its subsidiaries. "After evaluating the Company's strategic options, the Board of Directors unanimously concluded that it is in the best interests of the shareholders to dissolve and liquidate the Company," stated David Nassif, Chief Executive Officer. "The Board of Directors and management, together with its external advisors, devoted substanti
- SECSEC Form DEFA14A filed by Sio Gene Therapies Inc.DEFA14A - Sio Gene Therapies Inc. (0001636050) (Filer)
- NEWSOn December 14, 2022, The Board Of Directors Of Sio Gene Therapies Unanimously Approved The Dissolution And Liquidation Of The Company Pursuant To A Plan Of Complete Liquidation And DissolutionOn December 14, 2022, the Board of Directors of Sio Gene Therapies Inc. (the "Company") unanimously approved the dissolution and liquidation of the Company pursuant to a plan of complete liquidation and dissolution (the "Plan of Dissolution"), subject to shareholder approval. The Company intends to call a special meeting of the shareholders to seek approval of the Plan of Dissolution and will file proxy materials relating to the special meeting with the Securities and Exchange Commission as soon as practicable. A copy of the Plan of Dissolution is filed herewith as Exhibit 2.1 and incorporated herein by reference. A copy of the press release issued by the Company on December 14, 2022 ann
- SECSio Gene Therapies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Sio Gene Therapies Inc. (0001636050) (Filer)
- NEWSWhy Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day SessionGainers Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) shares jumped 140% to $0.6041 after the company entered into a definitive merger agreement with GRI Bio. Panbela Therapeutics, Inc. (NASDAQ:PBLA) gained 52% to $0.2175. Panbela received EMA opinion on orphan designation for Ivospemin in combination with Gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Immix Biopharma, Inc. (NASDAQ:IMMX) jumped 46% to $2.1695 after the company announced it has in-licensed BCMA-targeted next-
SIOX FAQ
6 questionsWhat does Sio Gene Therapies Inc. do?
Sio Gene Therapies, Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis. It has a license agreement...Where does SIOX stock trade?
Sio Gene Therapies Inc. (SIOX) is listed on NASDAQ.What sector and industry is SIOX in?
Sio Gene Therapies Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about SIOX?
Sio Gene Therapies Inc. has had 5 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $700.00 price target on 2022-02-01.What companies are similar to SIOX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SIOX side-by-side with any of them on Quantisnow.How can I track SIOX on Quantisnow?
Quantisnow aggregates Sio Gene Therapies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SIOX to receive live email and push alerts on every new disclosure.